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Abstract 
 
Introduction 
 
Transcatheter aortic valve replacement (TAVR) is a relatively new strategy for replacing the 
aortic valve. We elected to review our early experience to see if we could identify clinical 
characteristics at baseline or immediately following the procedure that would predict death 
within one year.  
 
Methods 
 
Charts for all patients assigned to receive TAVR procedure at St Mary’s Medical Center, 
Huntington, West Virginia between April 2013 and November 2016 were identified and 
reviewed.  A total of seventy-two cases were included. 
 
Results 
 
All-cause mortality rate at index hospitalization, 30 days, and 12 months was 5.6%(N=4), 
6.9%(N=5), 19.4%(N=14) respectively. Stroke rate at index hospitalization, 30 days, and 12 
months was 2.8%(N=2), 2.8%(N=2), 8.3%(N=6) respectively.  Major predictors of death were 
post procedure GFR, contrast volume, and number of antiplatelet agents therapy (AUC= 0.638, 
0.632, 0.637 respectively).  
 
Conclusion 
 
We found that post procedure GFR, less number of antiplatelet agents post procedure, and 
contrast volume may predict mortality within first 12 months post TAVR. Further studies 
focused on the above factors may be warranted.  
 
Keywords 
 
transcathether, aortic valve, percutaneous, mortality, hypertension, blood pressure, correlation, 
machine learning  
 
Introduction 
 
Transcatheter aortic valve replacement (TAVR) is a relatively new strategy for replacing the 
aortic valve in patients with severe aortic stenosis (AS) who are felt to be at significant or 
prohibitive risk for conventional surgical approach.1 The positive results from various 
randomized controlled trials (RCTs) led to rapid evolution of the procedure.2-4  Both balloon-
expandable and self-expandable valves showed comparable results as compared to surgical aortic 
valve replacement (SAVR).2, 3  Recently the procedure was approved to include intermediate 
surgical risk patients based on PARTNER 2 cohort.4  Although the very definition of the high 
risk population predicts a high mortality rate, we elected to review our early experience after 
performing more than 50 TAVR procedures to see if we could identify clinical characteristics at 
baseline or immediately following the procedure that would predict early death (death within one 
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year) in our high risk population. To facilitate such identification, we chose to employ various 
machine learning methods effective in predicting categorical outcomes.5  
 
Methods 
 
Charts of all patients assigned to receive TAVR procedure at St Mary’s Medical Center, 
Huntington, West Virginia between April 2013 and November 2016 were identified and 
reviewed.  A total of 72 high-risk cases were included.  One of these patients died prior to 
undergoing the procedure.  Pre-procedural, procedural, and post-procedural data were obtained 
and analyzed. The baseline characteristics of these patients are shown in Table 1. Primary 
outcomes were identified as all cause mortalities and strokes at index hospitalization, 30 days, 
and 12 months.  Secondary outcomes data were identified as access site complications, heart 
failure symptoms, renal failure, length of stay, and post-procedural valvular hemodynamics.  
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Table 1: Baseline patient characteristics 
 
 
Characteristic TAVR (N=72) 
Age-yr 80.4 ± 8.7 
Male sex—no. (%) 38 (53) 
STS score 10.4 ± 6.2 
NYHA Class III or IV no. (%) 69(95.8) 
KCCQ 12 29.6±11.6 
Coronary artery disease—no. (%)  
- One vessel 19(26.3) 
- Two vessels 10(13.8) 
- Three vessels 8(11.1) 
Previous CABG—no. (%) 20(27.7) 
Previous PCI—no. (%) 20(27.7) 
PCI within 30 days prior procedure—no. 
(%) 
5(6.9) 
Cerebrovascular disease--no. (%) 22(30.5) 
Peripheral vascular disease--no. (%) 35(48.6) 
Diabetes Mellitus --no. (%) 28(38.8) 
Hypertension—no. (%) 71(98.6) 
COPD—no. (%) 53(73.6) 
Oxygen dependent —no. (%) 20(27.7) 
Pre procedure GFR 56.3±23.0 
Atrial fibrillation —no. (%) 16(22.2) 
1st Degree AVB —no. (%) 15(20.8) 
RBBB—no. (%) 13(18) 
PPM/AICD —no. (%) 13(18) 
Aortic Valve Area – CM2 0.72±0.18 
Mean Gradient  —mmHg 51.1±12.2 
Left Ventricular Ejection Fraction — (%) 48.4±12.4 
Moderate or Severe mitral regurgitation —
no. (%) 
16(22.2) 
Mitral stenosis —no. (%) 15(20.8) 
 
Statistical analysis 
 
All analysis was performed using the open source program R. The data was cleaned by excluding 
variables with large numbers of missing values. Variables with more moderate amounts of 
missing values that had numeric data had the average value placed into missing value categories. 
Analysis of 72 subjects was then possible. Machine learning was performed on a dataset without 
missing values.  Parameters used for subsequent analysis are shown in Table 1. Before deciding 
to analyze the dataset without missing values, multiple methods of imputation for both missing 
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categorical and continuous data were employed and yielded results similar to analysis on the 
cleansed data. 
 
Logistic Regression and Support Vector Machine 
 
We used a generalized linear (logistic regression) model as our default 6 using only baseline 
variables for the prediction of composite endpoint outcomes. In addition, we examined the utility 
of a support vector machine (SVM) which involves the multi-dimensional sorting of data based 
on the development of a hyperplane which best segregates the two classes.8 Using the CARET 
package, we employed two tuning parameters to control the performance of the SVM: kernel and 
C. We used the radial kernel option from the CARET package. When radial kernel is applied, 
Sigma needs to be specified to avoid over-fitting. The second tuning parameter used was C 
which specifies the penalty for misclassification. The best combination of C and Sigma values 
are determined using cross-validation. Sigma and C values were optimized within the CARET 
package, and values of 1e-4 and 32 were used thereafter.  
 
Random Forest 
 
The third method we applied is the random forest which employs decision trees to construct a 
predictive model using a set of binary rules applied to calculate a target value. We used two 
tuning parameters for random forest: the number of trees (ntree) averaged (1000) and the number 
of variables (mtry=9) randomly sampled as candidates at each split in each tree. The mtry 
parameter was varied and optimized using the ROC on the training set.7.8  
 
Neural Network   
 
We also tried a feed-forward neural network. Different feed forward neural network architectures 
were explored using the nnet and neuralnet packages.9  We found optimal performance with one 
hidden layer containing 9 hidden neurons with a decay value 0.24 after initial exploration.  
 
Model Comparisons 
 
The CARET package was used for comparison of the mature models employing 10 folds and 3 
repeats.10 Other packages within R were used for different specific tasks (e.g., nnet for 
construction of the neural network, random forest (randomForest) for constructing random 
forests).9,11-15 All numeric data were centered and scaled prior to analysis with all of the above 
methods. The R code used for these analyses is shown in appendix 1. 
 
Training and Test Sets  
 
In the first phase, we varied tuning parameters on a training subset with the CARET package. 
For the support vector machine, the sigma and c values were varied from 0.1 to 1. Once these 
parameters were optimized for the different methods, we used different seed values to split the 
training and testing sets (50% training:50% testing). We then employed the strategy of 3 repeats 
of the 10 folds with CARET on the different training subsets achieved varying the seed to initiate 
randomization to divide the set into training and testing subsets.  
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 Results 
 
A total of 72 patients underwent TAVR.  One patient died before getting the assigned procedure. 
Transfemoral access was 88.9%(N=64), Transapical access was 11.1%(N=8). The characteristics 
of the patients at baseline are shown in Table 1.  Valve types used are shown in Table 2.  
 
Table 2: Valve types 
        Valve Type           Number 
Sapien                 38 
Sapien XT                 20 
CoreValve                 10 
Sapein 3                  4 
 
Death and Stroke 
 
Death rate from any cause at 12 months was 19.4%(N=14) of which 4(5.6%) died during index 
hospitalization and one (1.3%) at 30 days. Stroke incidence at 12 months was 8.3%(N=6) of 
which two patients (2.8%) had stroke during index hospitalization, no new cerebrovascular 
events at 30 days.  
Major multivariate predictors of death from any cause at 12 months are presented in Table 3 and 
Figure 1.  Comparison of those with and without early death (< 12 months) is shown in Table 4.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
36
Marshall Journal of Medicine, Vol. 4 [2018], Iss. 4, Art. 6
https://mds.marshall.edu/mjm/vol4/iss4/6
DOI: http://dx.doi.org/10.18590/mjm.2018.vol4.iss4.6
Table 3: Mean and Standard Error of Mean (SEM) of Receiver Operator Curve (ROC) values 
utilizing different techniques. Top five predictor variables of death at 12 months.   
 
 
Model 
AUC mean+/SEM  
      RForest  
    0.64+/0.02 
         SVM 
0.57+/0.01 
     Nnet 
0.59+/0.01 
      Rpart 
0.51+/0.02 
     GLM 
0.61+/0.03 
  
  
  
  
  
  
  
  
  
  
  
 V
ar
ia
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tion 
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# GFR; Glomerular Filtration rate  
$ Contrast. Vol; Contrast volume in ML 
% Post.Pro.EF; Post procedure Ejection Fraction 
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Figure 1: Receiver operator curves (ROC) in one of the techniques showing sensitivity against 
specificity for generalized linear model (GLM)  
– red color, area under curve (AUC) = 0.56, support vector machine (SVM)  
– green color, AUC=0.63, neural network (NNet)  
– orange color, AUC= 0.63, random forest (RFor)  
– purple color, AUC= 0.63  
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Table 4: Comparison of those with and without early death (< 12 months) 
 
Variable Death < 12 
months 
(N=14) 
Alive >  
12 months 
(N=58) 
P-value 
Age 81.9+/-8.2 
 
80.2+/-8.9 NS 
Gender 7M/7F 31M/27F NS 
DM 5 23 NS 
HTN 14 57 NS 
STS Score 0.11+/-0.10 0.10+/-0.05 NS 
Coronary Arteries with 
Narrowing  
0.93+/-1.27 0.86+/-0.98 NS 
Prior PCI 2 
 
18 NS 
 
Prior CABG 3 17 NS 
Coronary Intervention 
within 30 days prior 
0 5 P<0.05 
 
PAD 7 28 NS 
 
Carotid Artery Stenosis 4 18 NS 
 
Pre. PPM. AICD 4 9 NS 
AVB 1st degree 3 12 NS 
Pre-procedure. LBBB 0 4 NS 
 
Post-procedure. LBBB 5 19 NS 
New. PPM 2 3 NS 
 
Pre-RBBB 4 9 NS 
 
Pre-Atrial Fibrillation 2 
 
14 NS 
Post-Atrial Fibrillation 3 16 NS 
Post procedure Aortic 
regurgitation grade 
1.1+/-0.9 1.1+/-0.9 NS 
 
COPD/Lung disease 8 45 NS 
Oxygen treatment 6 14 NS 
Pre-procedure GFR 47+/-26 59+/-22 NS 
 
 
Post-procedure GFR  47+/-21 58+/-21 NS 
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 Contrast (ml) 92+/-84 111+/-44 NS 
 
 
Hemoglobin (Pre, 
gm/dl) 
11.5+/-2.0 11.5+/-1.6 NS 
Hemoglobin 
(Discharge, gm/dl) 
9.9+/-0.6 10.5+/-1.2 NS 
Platelets (Pre, 
x10^3/ul) 
192+/-52 199+/-114 NS 
Platelets (Discharge, 
x10^3/ul) 
164+/-74 158+/-76 NS 
Blood transfusion  7 17 NS 
Sheath access 11 52 NS 
Baseline EF (%) 49+/-15 48+/-11 NS 
Post-procedure EF 55+/-14 52+/9 NS 
Pre Aortic Valve Area 
(cm^2) 
0.71+/-0.15 0.76+/-0.19 NS 
Post Aortic Valve Area 
(cm^2) 
2.12+/-0.45 2.55+/-2.29 NS 
LVID Pre (mm) 45.1+/-8.4 46..8+/-7.3 NS 
 
IVSD (mm) 13.3+/-2.1 12.4+/-2.8 NS 
LVOT diameter (mm) 21.4+/-1.9 20.7+/-1.9 NS 
 
LVOT area (mm^2) 35.8+/-6.6 33.6+/-6.1 NS 
Mean gradient (pre, 
mmHg) 
55.57143 50.0+/-11.6 NS 
Mean gradient (post, 
mmHg) 
14.2+/-8.7 9.9+/-4.1 
 
NS 
Mitral regurgitation 
(degree 0-4+) 
1.64+/-1.21 1.60+/-1.05 NS 
Mitral stenosis (N) 1 19 NS (p=0.054) 
NYHA class (pre) 3.1+/-0.4 3.3+/-0.6 NS 
NYHA class (post) 2.0+/-1.1 1.4+/-0.8 NS 
 
Anticoagulation (N) 1 18 NS (p=0.068) 
Antiplatelet (number of 
drugs) 
1.2+/-0.9 
 
1.6+/-0.6 P<0.05 
Access site 
complication (N) 
0 4 NS 
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Groin hematoma (N) 0 3 NS 
Duration of 
hospitalization (days) 
7.6+/-5.5 4.1+/-2.4  
 
 
Procedure outcomes 
 
The procedure was aborted in one patient due to inability to pass the valve through transfemoral 
approach. Patient died before getting transapical approach.  None of the patients required 
conversion to open surgical approach. A total of 5 (6.9%) patients required PCI at or within 30 
days prior to the procedure. All transfemoral (88.9%, N=64) approach patients performed 
utilizing arterial cut down for sheath access.  Combined access site complications rate was 
5.6%(N=4). Major and minor access site hematoma rate was 4.2%(N=3). 33.3%(N=24) patients 
required at least 1 unit of red blood cell transfusion.  Mean contrast volume was 108 milliliters.  
 
Other clinical outcomes 
 
There was a significant reduction in symptoms to New York Heart Association (NYHA) class I 
or II at follow up visits. There was a significant increase in Kansas City Cardiomyopathy 
Questionnaire (KCCQ) points at 30 days (P< 0. 02) and 12 months (P=<0.02) follow up. Mean 
KCCQ before TAVR was 29, which increased to 54 and 53 at 30 days and 1 year respectively.  
Mean post procedure GFR (55.9±23.2). Rate of new onset left bundle branch block (LBBB) was 
27.7%(N=20).  Five patients (6.9%)required new permanent pacemaker (PPM) placement. A 
total of 4(5.5%) patients developed new onset atrial fibrillation.   
 
Echocardiographic data 
 
Aortic Valve Area (AVA) showed a significant increase as compared to baseline (P= 
0.000000001662, t=-6.9), with a mean post procedure AVA of  (2.4 CM2 ±2.0).  There was a 
significant reduction in the mean gradient across aortic valve (P=< 0.022), average post 
procedure mean gradient (10.6 mmHg ± 5.3).   Mean post procedure aortic regurgitation 
including paravalvular and valvular jets was mild.  Ejection fraction showed improvement post 
intervention with mean value of 52% as compared to 48% pre-intervention relation to outcome 
are shown in Table 4.  
 
Discussion 
 
We evaluated the high-risk population who underwent TAVR at our institution at the very 
beginning of our TAVR program. Variable baseline risk factors and elevated pre-procedure 
Society of Thoracic Surgery (STS) risk score predict increased mortality.16 Interestingly, in our 
study the three major predictors of mortality within twelve months were procedural related 
factors, however no statistical significance was noted possibly due to small sample size.  Not 
surprisingly, two out of three elements were renal related. Acute Kidney Injury (AKI) is a 
frequently encountered complication post TAVR.17, 18 Several predictors of AKI have been 
studied.19 Pre existing chronic kidney disease, respiratory failure, blood transfusion, previous 
stroke, frequent intraprocedural valve reposition, periprocedural embolization, hemodynamic 
41
Yousef et al.: Outcomes of Transcutaneous Aortic Valve Replacement among high ri
Published by Marshall University's Joan C. Edwards School of Medicine, 2018
instability associated with rapid pacing, and use of contrast medium were strong predictors for 
acute kidney injury.18, 20   
 
In our study contrast media volume was a predictor for increased 12 months mortality.  
Nevertheless, limiting contrast use is a priority during TAVR; complexity of cases, however, 
may mandate the opposite. Interestingly, a meta-analysis of four cohort studies which included 
891 TAVR patients did not show a significant association between contrast media volume and 
risk of AKI, 21 however the small number of the included studies is a limitation of the analysis.  
Thus further studies may be warranted to evaluate whether contrast media volume alone without 
AKI is a potential independent surrogate for increase mortality post TAVR. New onset AKI 
demonstrated worse short and long prognostic impacts among TAVR population.  According to a 
meta-analysis of 5, 971 patients, post procedure AKI was associated with increased all cause and 
cardiovascular mortality early and at 12 months.22  RenalGuard system utilizing furosemide 
induced diuresis with matched isotonic saline may be an effective tool in reducing incidence of 
post TAVR AKI.23, 24 
 
Valve designs and procedural techniques have evolved significantly over the recent period. 
Lower valve profile has enhanced valve deliverability and reduced complications. Sheath size 
has decreased significantly from 24 French (Fr) to 14-16 Fr thus reducing the need for arterial 
cut down and access site complications.  Moreover, addition of an external skirt to the balloon 
expandable valves (Sapien XT, Sapien 3) reduced paravalvular regurgitation.25  In our sample 
only four patients demonstrated access site complications, however majority of the valves were 
early generation with higher profile and required arterial cut down in nearly all of the 
transfemoral cases.  Despite using early generation valves in the majority of cases, the mean 
degree of paravalvular regurgitation was mild. 
 
Thirty days and 12 months stokes rates were 2.8%(N=2), and 8.3%(N=6) respectively. Our 30 
days rate is lower than results reported in large prospective cohorts (2.8% vs. 5% in the 
PARTNER trial), while our 12 months results are comparable (8.3 vs. 7.8).3, 4  Neurological 
events post TAVR are classified as early within first 24-48 hours (procedural related), delayed 
between 2-30 days, and late after 30 days (patient and disease related factors).26 Small aortic 
valve area, balloon post dilatation, and atrial fibrillation are associated with increased incidence 
of early cerebrovascular accidents (CVAs). Chronic atrial fibrillation, prior cerebrovascular 
disease, and transapical approach are some predictors of late CVAs.27 Currently there is 
controversy about the benefit of embolic protection devices, however recent meta-analysis of 
randomized control trials demonstrated promising role in stroke reduction; future large studies 
may answer this question.28  
 
Sedation technique during the procedure has evolved since the advent of TAVR. Initially the 
procedure was only done under general anesthesia, as is the case in our early sample. However, 
currently most of the TAVR in our institution are performed under conscious sedation.  Hence 
ICU hours and cost of care have significantly reduced by using conscious sedation.29 Finally, we 
have noticed that mono-antiplatelet therapy (MAPT) in our population was a strong predictor of 
increased 12 months mortality.  The current consensus is utilizing heparin during the procedure 
and dual antiplatelet therapy (DAPT) for 6 months following the implantation of the valve.30 
Interestingly, a large meta-analysis showed conflicting results regarding dual versus single 
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antiplatelet therapy.31, 32  Analysis of nine studies, which included 7991 patients, demonstrated a 
significant reduction in mortality and a slight benefit in stroke prevention without increase in 
major bleeding, as compared to MAPT alone.31 Addition of oral anticoagulation to MAPT did 
not show any benefit when it compared to DAPT in the same meta-analysis. However, another 
meta-analysis of six studies which included 840 patients showed increased bleeding risk with 
DAPT, with no reduction in mortality, stroke, or myocardial infarction.32 Hence, despite its 
increasing use, the optimal antiplatelet management of patients undergoing TAVR remains 
uncertain. Given our small sample size, further multicenter studies are warranted to delineate the 
association between MAPT and mortality risk among TAVR population.  
 
In conclusion, we found that post procedure GFR, less number of antiplatelet agents post 
procedure, and contrast volume may predict mortality within first 12 months post TAVR. Further 
studies focused on the above factors may be warranted.  
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